RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1
RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1
PR Newswire
CAMBRIDGE, Mass., Nov. 13, 2026
CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ -- Biointron Biological USA Inc. ("Biointron") is pleased to have supported Molence Bio's Mol-1 project. Mol-1 demonstrates performance comparable to the leading closed-source model IsoDDE in antibody-antigen structure prediction and is capable of designing functional nanobodies from scratch. To experimentally evaluate these AI-designed candidates, Biointron conducted developability assays using RushDATA™, its wet-lab validation service for AI-designed antibodies.

The results: 23 out of 30 AI-designed candidates met at least three of the four developability criteria, demonstrating promising developability profiles.
Wet-Lab Validation with RushDATA™
AI-designed antibodies require experimental validation to demonstrate their potential as viable drug candidates. Biointron ran the developability panel on Molence Bio's VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.
Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.
Bridging AI Design and Wet-Lab Validation
RushDATA™ is Biointron's wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.
The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.
Why This Matters for AI-Driven Antibody Discovery
AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.
Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.
About Biointron
Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.
Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html
About Molence Bio
Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.
Access the model weights: https://github.com/molence/Mol-1
Contact
Media contact: Mia Deng
Biointron
+1 (732) 790-8340
info@biointron.com
20 University Road, Suite 500, Cambridge, MA 02138


SOURCE Biointron
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

